Second CGRP inhibitor listed by TGA

Fremanezumab (Ajovy)  is now listed on the Australian Register of Therapeutic Goods (ARTG) for the prevention of migraine in adults and is up for consideration for PBS listing at this month’s meeting of the PBAC. The migraine community are hopeful the CGRP inhibitor, marketed by Teva, will be recommended for PBS subsidy, as its competitor ...

Already a member?

Login to keep reading.

© 2021 the limbic